companies / cardurion-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 260,000,000260.0M | ○ |
|---|---|---|
| founded | null | |
| hq | Burlington MA | |
| industry | unknown | |
| stage | series-b+ |
Cardurion Pharmaceuticals develops cardiovascular treatments centered on PDE9 inhibition for heart failure and CaMKII inhibition for arrhythmias and rare heart conditions. It targets patients with chronic heart failure and rare genetic diseases like CPVT who lack adequate therapies today. The company is the first to advance a CaMKII inhibitor through clinical studies, opening multiple cardiac indications around the mechanism.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-07-01 | series-b | 260,000,000260.0M | null | ○ |
Cloudflare, WordPress, Yoast SEO 27.4, Google Tag Manager, Gravity Forms 2.10.2, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.3, Essential Addons for Elementor, Cloudflare Bot Management, ZURB Foundation, WP Engine
| fact | status | src |
|---|---|---|
| Series B, $260.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |